---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-063326"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:01:47.073665+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ProKidney Q3 net loss widens to $42M; cash runway into Q4 2025

## Summary
- Net loss $42.0M for Q3 2023 vs $33.9M for Q3 2022, driven by higher R&D costs.
- Cash, equivalents and marketable securities $396.3M at Sep 30, down from $490.3M at Dec 31, 2022.
- R&D expenses $32.2M in Q3 2023 vs $21.1M in Q3 2022, up 53% on clinical trial and staffing costs.
- G&A expenses flat at $14.4M; equity-based compensation offset prior-year business combination costs.
- Cash expected to fund operations into Q4 2025; 235.4M ordinary shares outstanding at Sep 30.

## SEC filing metadata
- accession: 0000950170-23-063326
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000095017023063326/0000950170-23-063326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000095017023063326/prok-20231114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-063326
- JSON: https://secwatch.observer/filing/0000950170-23-063326.json
- Plain text: https://secwatch.observer/filing/0000950170-23-063326.txt

## Key facts
- Earnings Releases
  PROKIDNEY CORP. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 14, 2023, ProKidney Corp. issued a press release to announce its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000095017023063326/0000950170-23-063326-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.